(Q43861572)

27 November 2017

Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring (English)

1 reference

27 November 2017

1 reference

Vosse M

1

1 reference

27 November 2017

Renard F

2

1 reference

27 November 2017

Coibion M

3

1 reference

27 November 2017

Neven P

4

1 reference

27 November 2017

Nogaret JM

5

1 reference

27 November 2017

Hertens D

6

1 reference

27 November 2017

1 February 2002

1 reference

European Journal of Obstetrics Gynecology and Reproductive Biology

27 November 2017

1 reference

27 November 2017

101

1 reference

27 November 2017

1

1 reference

27 November 2017

58-63

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Incidence of New Primary Cancers After Adjuvant Tamoxifen Therapy and Radiotherapy for Early Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Endometrial lesions in patients undergoing tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Surveillance for endometrial cancer in women receiving tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Gynecologic effects of tamoxifen and the association with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Should tamoxifen users be screened for endometrial lesions?

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Longitudinal hysteroscopic follow-up during tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Risk of endometrial cancer after tamoxifen treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Uterine side effects of tamoxifen: a need for systematic pretreatment screening

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

Guidelines for monitoring patients taking tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2801%2900516-4

7 January 2021

10.1016/S0301-2115(01)00516-4

Identifiers

DOI

1 reference

27 November 2017

1 reference